Monday, September 16, 2024
Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.
Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Strong fiscal Q4. SelectQuote’s fiscal Q4 revenue of $307.2 million and adj. EBITDA of $14.4 million exceeded our estimates of $271.3 million and a loss of $2.2 million, respectively. In our view, the strong performance demonstrated the power of the company’s synergistic business model, which serves consumers’ needs both for insurance policies and pharmacy services.
Pharmacy momentum. Total revenue grew an impressive 38% over the prior year period, driven largely by the company’s Healthcare Services segment, which is comprised primarily of SelectRx (home-direct pharmacy business). Healthcare Services revenue was up roughly 75%, year-over-year with SelectRx membership growing to approximately 82,000, up from roughly 75,000 at the end of fiscal Q3.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
